Welcome to our Digital Treatment Map

A practical, expert-led, and evidence-based resource designed to help you navigate the different treatment lines of ALK and ROS1 mutation positive NSCLC.

Join Dr Barbara Melosky, Dr Solange Peters, and Dr Ross Camidge as they guide you through this independent educational map for North American and Western European practice, providing expert insight together with the latest data to aid your own clinical decision making.

Suitable for medical oncologists, surgeons, pulmonologists and other HCPs involved in the care and treatment of patients with NSCLC, particularly in Canada, the United States, and Western Europe.

Published: 12 December 2021
Estimated time to complete: 30 minutes

Watch the introductory video to find out more

Looking for a practical resource to guide your practice and aid clinical decision making? Our experts talk about how this treatment map will work for you.

Introduction to the program

Keep up to date on the evolving treatment landscape of advanced ALK and ROS1 mutation positive NSCLC.

This map combines the most recent evidence-based guidance from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) with the latest clinical trial data, supplementary expert opinion videos, and current literature on managing adverse events after tyrosine kinase inhibitor therapy

Click on the different treatment lines and select the information that interests you.

Learning objectives

After utilizing this digital treatment map, healthcare practitioners will be able to:

Expert faculty

Dr Barbara Melosky

University of British Columbia, Canada

Dr Melosky is a Clinical Professor of medicine at the University of British Columbia and a medical oncologist in Vancouver at the British Columbia Cancer Agency. She specializes in the field of thoracic malignancy and is head of the Lung Tumor Group at BC Cancer.

Dr Melosky sits on the Executive Lung Site Committee for Canadian Clinical Trials Group CTTG. She has chaired the Canadian Lung Cancer Conference for the last 21 years, attended by over 500 participants. Dr Melosky organizes and chairs the Lung Cancer Journal Club, as well as chairing, and creating, the British Columbia Lung Cancer Biobank.

She is published extensively and is considered a national and international expert in thoracic malignancies.


Dr Melosky discloses sitting on the Advisory Board and receiving honorarium from Roche, Lilly, Bristol Myers Squibb, Merck, Pfizer, Boehringer Ingelheim, AstraZeneca, Jazz, Amgen, and Takeda.

All relevant financial relationships have been mitigated.

Professor Solange Peters

University Hospital of Lausanne, Lausanne, Switzerland

Professor Peters is a full professor and chair of medical oncology and the thoracic malignancies program in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Professor Peters is currently in charge of teaching and patient care in thoracic malignancies at Lausanne University, where she is building a translational program in collaboration with the Swiss Federal Institute of Technology and the Ludwig Institute. Her main fields of interest are new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. Her current research projects are mainly focused on innovative immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator and Foundation Council member of the European Thoracic Oncology Platform.

Professor Peters has authored numerous peer-reviewed manuscripts and book chapters, is an Associate Editor of the Annals of Oncology, serves on the editorial board of several other oncology journals, and was the Deputy Editor of the Journal of Thoracic Oncology for 10 years. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) where she created the Women for Oncology Committee, and for which she is the youngest President to have served for an extended time of 3 years (from 2020 to 2022), and the International Association for the Study of Lung Cancer (IASLC), where she was a previous member on the Board of Directors.


Professor Peters discloses education grants, the provision of consultation and attendance on advisory boards and/or provided lectures for the following organizations, (all honoraria payments have been given to her institution).

Consultation and/or advisory roles were carried out for for AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, Foundation Medicine, Illumina, IQVIA, Incyte, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda.

Speaker roles were carried out for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda.

Professor Peters also received Grants and research support for (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, and Pfizer, Phosplatin Therapeutics, Roche/Genentech.

All relevant financial relationships have been mitigated.

Dr Ross Camidge

University of Colorado Cancer Centre, Denver, USA

Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Ross Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.

Dr Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 300 academic publications, including in the Journal of Thoracic OncologyThe Lancet Oncology, and New England Journal of Medicine.

Dr Camidge has received numerous awards including the Bonnie J Addario International Lectureship Award and The Lung Cancer Foundation’s Breath Away From The Cure Award. Every year from 2017, he has been internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. In 2019 and 2020 he was ranked at the ‘World Expert’ level by Expertscape and recognized to be in the top 0.0043% of scholars writing about Lung Neoplasms over the past 10 years. He is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) – a collaborative network of 15 US and Canadian sites conducting trials in thoracic oncology, Co-chair of the Elsevier ClinPath (formerly VIA) Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.


Dr Camidge discloses sitting in advisory roles with ad hoc advisory boards/consultations for Abbvie, Apollomics (SRC), AstraZeneca (SRC/SC), Blueprint, Daiichi-Sankyo (ILD adjudication committee), Elevation (SRC), Eli Lilly (DSMB and NCCN), Helsinn (DSMB), Kestrel (SAB), Nuvalent (SAB), Puma (NCCN), Ribon, Roche, Sanofi, Seattle Genetics, Takeda, Turning Point (all during the period of 2021).

In 2020 for  Amgen, Anchiarno (SAB), Apollomics (SRC), AstraZeneca, Bio-Thera (DSMB), BMS, Daiichi-Sankyo (ILD adjudication committee), Eisai, EMD Serono, Elevation (SRC), Eli Lilly, GSK, Helssin, Janssen, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, Takeda.

During 2019 this was also the case for Takeda, CBT Pharmaceuticals, Daiichi-Sankyo (ILD adjudication committee), G1 Therapeutics (DSMB), Bio-Thera (DSMB), Blueprint, Abbvie, Achilles, BeyondSpring, Apollomics (SRC), 14ner/Elevation (SRC), Archer, EMD Serono, Helssin, BMS, Eli Lilly, Medtronic, Ribon. Dr Ross Camidge discloses receiving Research funding from Inivata.

Dr Camidge was also involved in company sponsored trials at institution (PI roles) for Abbvie, AstraZeneca, Dizal, Inhibrx, Karyopharm, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point during the period of 2019-2021.

All relevant financial relationships have been mitigated.

Educational grant

This independent content was supported by an educational grant from Pfizer.

Contact us

Springer Healthcare IME

Before you go!

Have you used our digital treatment map? If so, we’d love your feedback! Click the button below to take our short evaluation survey. We really appreciate your feedback which helps guide our future educational offerings.